At a glance
Adults 18+ COVID-19 Vaccination Coverage and Intent
Weekly estimates of COVID-19 vaccination coverage and intent for vaccination among adults are calculated using data from the National Immunization Surveys (NIS)-Fall Respiratory Virus Module (NIS-FRVM). The NIS–FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon self-reported receipt of vaccination and month of that vaccination.
Weekly comparisons to previous season should take into account differences between seasons in vaccine availability dates. 2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 and 2025–26 COVID-19 vaccines were first available at the end of August 2024 and 2025, respectively.
The NIS-FRVM data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel. This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
- Figure 3A. COVID-19 Vaccination Coverage, Overall and by Selected Demographics and Jurisdiction, Among Adults 18 Years and Older, by Season*,†,‡,§,±. Data Source: National Immunization Survey-Fall Respiratory Virus Module.
- Figure 3B. Weekly COVID-19 Vaccination and Intent for Vaccination^, Overall and by Selected Demographics and Jurisdiction, Among Adults 18 Years and Older, by Season*,†,‡,§,±. Data Source: National Immunization Survey-Fall Respiratory Virus Module.
Download data for Figures 3A & 3B
- Figure 3C. Weekly Cumulative COVID-19 Vaccination Coverage Map and Comparison Between 2025–26 and Previous Seasons by Jurisdiction, Adults 18 Years and Older, United States*,†,‡,€. Data Source: National Immunization Survey-Fall Respiratory Virus Module.
- Figure 3D. Differences in Cumulative COVID-19 Vaccination Coverage by Selected Demographics and by Season, Adults 18 Years and Older, United States*,†,‡,§,±. Data Source: National Immunization Survey-Fall Respiratory Virus Module.
Note: In the past seasons NIS-FRVM was referred to as the NIS-Adult COVID Module (NIS-ACM).
Confidence Intervals (CIs) describe the level of uncertainty around an estimate because a sample was taken. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% confidence interval, if the sampling method is repeated many times, the true value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
Estimates from the NIS-FRVM may differ from estimates based on other data sources, and in addition to random error associated with taking a sample, are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
*National estimates include 50 states, Washington D.C., Puerto Rico, and U.S. Virgin Islands (included in 2021, 2023, and 2025 calendar years). The Office of Intergovernmental and External Affairs hosts 10 Regional Offices that directly serve state and local organizations; information about Regions and which states are included in each region is available.
†Vaccination coverage with the 2025–26 COVID-19 vaccine is defined as receipt of at least one vaccination since September 1, 2025. Vaccination coverage estimates are based on all interviews through the current week and represent approximately the cumulative percent vaccinated by mid-week. Each week, estimates for prior weeks are recalculated using the additional interviews conducted that week (combined with all previous interviews).
‡Cumulative vaccination coverage estimates are suppressed when the cumulative sample size is <30 or current week sample size is <5. Vaccination intent estimates for a given week are suppressed when the sample size for that week is <30.
§For 2025–26, a demographic variable was added for presence of underlying conditions that are associated with a higher risk for severe COVID-19. NIS-FRVM respondents were asked "Do you have a health condition that may put you at higher risk for getting very sick from respiratory diseases, such as the flu, RSV, or COVID?". If the respondent replied yes, they were asked what that condition was. Respondents were categorized as having a high-risk condition if they listed any of the following conditions: cancer, chronic kidney disease, chronic lung diseases including asthma, dementia or other neurological conditions, diabetes, Down syndrome, heart conditions, HIV infection, weakened immune system, liver disease, overweight, pregnancy, sickle cell disease or thalassemia, smoking, solid organ or blood stem cell transplant, stroke or cerebrovascular disease, or reside in a nursing home.
±The 'Multiple or Other Races, Non-Hispanic' category includes non-Hispanic persons who selected multiple races or a race other than American Indian/Alaska Native, Asian, Black, Native Hawaiian or other Pacific Islander, or White.
^Estimates for vaccination intent are based on interviews conducted during that week and are adjusted to the cumulative vaccination coverage estimate for that week.
€Interpretation of the difference between current minus previous season is based on the 95% confidence interval (CI) of the difference. The interpretation is "Similar to last season" if the 95% CI for difference overlaps with zero; "Lower than last season" if the entire 95% CI for the difference is below zero; and "Higher than last season" if the entire 95% CI for the difference is above zero.